Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Incyte's Oncology Strategy: Putting Its Eggs In Many Mechanistic Baskets

Executive Summary

Commercial success with Jakafi allows parallel development of many new cancer drug mechanisms beyond the IDO1 inhibitor epacadostat, which is on a fast track.


Related Content

Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio
Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor
Broad-Based Incyte/Merus Collaboration Includes Up To 11 Bispecific Antibody Programs
Sanofi Could Pursue Other Oncology M&A Targets After Medivation Loss


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst